Gilead Sciences: Innovations in Healthcare

Gilead Sciences is a biopharmaceutical company known for its research and development of innovative medications, particularly in the fields of HIV/AIDS, liver diseases, and COVID-19.
Category
Company
Where to get
Products available through healthcare providers and pharmacies.
Applicable for
Prepared by Shruti Sahoo, reviewed by Dr. Eugene Smith

Gilead Sciences FAQ


Image credit: logos-download.com

Who is Gilead Sciences?

We’ve been taking on the world’s biggest health challenges for more than 35 years. We continue to set and achieve ambitious goals to create a healthier world for all people. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Is Gilead a biopharmaceutical company?

Gilead Sciences, Inc. ( / ˈɡɪliəd /) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

What does Gilead do?

We’re working with organisations around the world as well as in Australia and New Zealand to eliminate healthcare inequities and promote social justice. At Gilead, we strive to transform and simplify care for people with life-threatening diseases around the world.

Did Gilead Sciences make a profit?

Let’s take a closer look at Gilead Sciences’ first step on the road to success. After Riordan financed the company’s resettlement to Foster City, California, all operations took off. The corporation was able to generate $1.3 million in revenue by the end of the first fiscal period. But did this revenue result in a profit? No, it did not.

Gilead Sciences References

If you want to know more about Gilead Sciences, consider exploring links below:

Explore Related Topics

How do new antiviral medications work differently from traditional antibiotics?

This thread discusses the mechanisms of action of new antiviral medications compared to traditional antibiotics, highlighting the differences in targeting viral infections.